Daniel A. Harki
Affiliations: | 1999-2005 | Medicinal Chemistry | University of Minnesota, Twin Cities, Minneapolis, MN |
Google:
"Daniel Harki"Mean distance: 8.75 | S | N | B | C | P |
Parents
Sign in to add mentorBlake R. Peterson | grad student | 1999-2005 | Penn State | |
(Chemical synthesis of base-modified ribonucleosides as novel antiviral agents.) | ||||
Peter B. Dervan | post-doc | 2005-2009 | Caltech |
Children
Sign in to add traineeJacob T. Edwards | research assistant | 2012-2014 | UMN |
Stephanie L. Breunig | research assistant | 2014-2016 | UMN |
Caitlin Puro | research assistant | 2015-2017 | UMN |
Dan Wang | grad student | 2009-2013 | UMN |
Timothy E. Andrews | grad student | 2010-2013 | UMN |
Margaret E. Olson | grad student | 2010-2015 | UMN |
Nicholas Struntz | grad student | 2009-2016 | UMN |
John C. Widen | grad student | 2011-2017 | UMN |
Anand Divakaran | grad student | 2015-2021 | UMN |
Constance B Anderson | post-doc | UMN | |
Frederick A. Meece | post-doc | 2009-2010 | UMN |
Brian R. White | post-doc | 2009-2010 | UMN |
Dennis A. Brown | post-doc | 2010-2011 | UMN |
Tianshun Hu | post-doc | 2009-2012 | UMN |
Aaron M. Kempema | post-doc | 2012-2014 | UMN |
Dibyendu Dana | post-doc | 2014-2015 | UMN |
Ruben Eckermann | post-doc | 2016-2017 | UMN |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Divakaran A, Harki DA, Pomerantz WCK. (2023) Recent progress and structural analyses of domain-selective BET inhibitors. Medicinal Research Reviews |
Divakaran A, Scholtz CR, Zahid H, et al. (2022) Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader. Acs Medicinal Chemistry Letters. 13: 1621-1627 |
Moghadasi SA, Esler MA, Otsuka Y, et al. (2022) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells. Mbio. e0078422 |
Ghani LA, Yusenko MV, Frank D, et al. (2022) A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells. Cancer Letters |
Cui H, Divakaran A, Hoell ZJ, et al. (2022) A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes. Journal of Medicinal Chemistry |
Cui H, Carlson AS, Schleiff MA, et al. (2021) 4-Methyl-1,2,3-Triazoles as -Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity. Journal of Medicinal Chemistry |
Jackson PA, Schares HAM, Jones KFM, et al. (2020) Synthesis of Guaianolide Analogues with a Tunable α-Methylene-γ-lactam Electrophile and Correlating Bioactivity with Thiol Reactivity. Journal of Medicinal Chemistry |
Pomerantz WCK, Cui H, Divakaran A, et al. (2020) Selective N-terminal BRD4 bromodomain inhibitors by targeting non-conserved residues and structured water displacement. Angewandte Chemie (International Ed. in English) |
Passow KT, Antczak NM, Sturla SJ, et al. (2020) Synthesis of 4-Cyanoindole Nucleosides, 4-Cyanoindole-2'-Deoxyribonucleoside-5'-Triphosphate (4CIN-TP), and Enzymatic Incorporation of 4CIN-TP into DNA. Current Protocols in Nucleic Acid Chemistry. 80: e101 |
Kvach MV, Barzak FM, Harjes S, et al. (2019) Differential inhibition of APOBEC3 DNA-mutator isozymes by fluoro- versus non-fluoro-substituted 2'-deoxyzebularine embedded in single-stranded DNA. Chembiochem : a European Journal of Chemical Biology |